A paper in Cell Reports Medicine, 22nd January 2024, linked below, states that Docetaxel effectiveness can be extended by using Dicyclomine both before resistance and after resistance. This was also reported in the Times last week.
................................................................
'Dicyclomine, a clinically available CHRM1-selective antagonist, reverts resistance and restricts the growth of multiple docetaxel-resistant CRPC cell lines and patient-derived xenografts. Our study reveals a CHRM1-dictated mechanism for docetaxel resistance and identifies a CHRM1-targeted combinatorial strategy for overcoming docetaxel resistance in PC.'
............
As this is a paper it presumably is some way off being a treatment.
Edited by member 30 Jan 2024 at 17:59
| Reason: Complete re-write based on finding the original report.